Abstract
Background CoViD-19 deaths per capita are often used to compare the progression of the disease across populations. This article discusses alternative comparative measures based on well-established practices in demography.
Methods Using extant estimates, we calculate CoViD-19 death rates for 263 countries, territories, provinces in China and US states. We indirectly standardize 250 of these rates using population age-and-sex distributions. Using extant projections and life tables, we calculate reductions in 2020 life expectancy at birth for 108 countries and states.
Results To date, New York has the highest of the 263 CoViD-19 death rates, exceeding the state’s 2017 Crude Death Rate for the period between March 14 and May 20. Relative to the US, standardization lowers European rates but increases South American rates. When both can be calculated, indirectly and directly standardized rates are very close. Reductions over one year in 2020 life expectancy at birth are projected in 3 countries and 7 states, even exceeding 2 years in New York.
Conclusions Our results validate indirect standardization as a valuable alternative, especially for small areas where age-and-sex CoViD-19 data might be unavailable or unreliable. Uncertainty about CoViD-19 trajectories remains substantial, but current projections seem more likely to under-than to over-estimate the eventual impact of CoViD-19 on the annual life expectancy at birth. For the US, they suggest that by October 1 that impact would reach twice the impact of HIV infections or opioid overdoses, reducing the 2020 life expectancy to its lowest level since 2008.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Publicly available data only
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available online and can be accessed directly or through a web scraping routine that we provide at https://github.com/statsccpr/ind-cov-mort
https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
